Written by Dr. Ryan, DO
Updated September 30, 2026
Not sure if your VA claim is worth pursuing?
Run your case against 295,756 actual BVA appeal decisions. 5 minutes. No payment. No obligation.
Free Viability Check →This one comes up constantly and most veterans don't realize it's an option.
The VA does not rate obesity as a standalone disability. You can't get service-connected for being overweight. But obesity can serve as an intermediate step connecting a service-connected condition to a new secondary condition.
Here's how it works in practice. Say you have service-connected knee injuries that limit your mobility. You can't run, can't hike, can't exercise the way you used to. Over the years, you gain weight. Now you have sleep apnea, or your back is giving out, or you've developed type 2 diabetes. Each of those conditions has a well-documented relationship to obesity.
The causal chain is: knees (service-connected) caused reduced mobility, reduced mobility caused weight gain, weight gain caused the new condition. Each link needs to be supported by medical evidence.
Where veterans get tripped up is filing for the new condition without establishing the obesity link first. If you submit a nexus letter connecting your back pain to your knees but skip over the obesity step, the VA will deny it because there's no direct orthopedic mechanism connecting knee injuries to lumbar spine disease. The obesity intermediate step is what makes the chain work.
The same logic applies to psychiatric medications. PTSD treated with sertraline and quetiapine leads to weight gain, weight gain leads to sleep apnea. The medication side effect is the intermediate link.
If you're filing a secondary claim and weight gain is part of the picture, make sure the nexus opinion explicitly addresses every step in the chain; that's part of what makes a nexus letter strong. A gap anywhere is where the denial happens.
In 2017 the VA's General Counsel issued a precedent opinion, VAOPGCPREC 1-2017, that settled how this works. Obesity by itself is not a disease or injury that can be service-connected. It can, however, be an intermediate step between a service-connected disability and a new condition. The opinion frames three questions:
A nexus opinion that only addresses the last link, or treats the weight gain as a given, leaves the first question open. The strongest opinions take each question in order and point to the records that answer it.
Weight gain in veterans with PTSD is often attributed to lifestyle factors like reduced activity or increased caloric intake. Those factors are real, but they miss the most documentable driver: the medications used to treat service-connected PTSD carry well-characterized weight-gain profiles. For veterans with PTSD, obesity matters in three ways:
This class carries the highest weight-gain risk of any PTSD pharmacotherapy. Quetiapine (Seroquel), widely used for sleep in PTSD, olanzapine (Zyprexa), and risperidone (Risperdal) all carry clinically significant metabolic effects. Published data shows that olanzapine in particular produces an average weight gain of several kilograms within weeks of starting it, with ongoing weight accumulation over months to years. The mechanism involves histamine H1 receptor blockade, which drives appetite and reduces satiety signaling, combined with serotonin 5-HT2C antagonism.
Long-term SSRI and SNRI use is associated with modest but cumulative weight gain. Paroxetine has the most documented weight-gain profile among SSRIs. Mirtazapine, sometimes used as an adjunct for PTSD sleep and appetite, causes significant weight gain through antihistamine and antiserotonergic mechanisms.
The medication version of the chain is: service-connected PTSD, then PTSD medication with a documented weight-gain profile, then clinically significant weight gain documented in your records, then the secondary condition. The records that support it:
Ideally, the records show that weight gain began or accelerated after a specific medication was started. That temporal relationship is the evidentiary core of the claim.
Type 2 diabetes can follow the standard chain: medication causes weight gain, weight gain produces insulin resistance, and insulin resistance progresses to diabetes. But atypical antipsychotics also have direct, non-weight-mediated effects on insulin secretion and glucose regulation. Published endocrinology literature documents higher rates of new-onset type 2 diabetes with atypical antipsychotics than in untreated populations, independent of weight gain. That direct effect is an additional nexus pathway that doesn't depend on obesity as the intermediate step.
Obesity is one of the strongest risk factors for obstructive sleep apnea. When PTSD medication caused significant weight gain and that weight gain drove a sleep apnea diagnosis, the three-link chain is PTSD, then medication-related weight gain, then sleep apnea. For more, see Can PTSD cause sleep apnea? and PTSD secondary conditions: the 10 most commonly overlooked.
The same few problems come up again and again:
For a medication-driven obesity chain, the opinion should:
That takes your complete medication and weight history. Without it, the physician can't write a specific, defensible opinion.
Fully refundable $149 deposit at intake. $400 only if we can support your claim.